# Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids

> **NCT01603277** · PHASE2 · COMPLETED · sponsor: **Humanigen, Inc.** · enrollment: 160 (actual)

## Conditions studied

- Moderate-to-Severe Asthma

## Interventions

- **BIOLOGICAL:** Anti-GM-CSF Monoclonal Antibody 400mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01603277
- **Lead sponsor:** Humanigen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2013-07
- **Final completion:** 2014-01
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2015-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01603277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01603277, "Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01603277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*